FilingIndex
← The Wire
AKTSNasdaq

Aktis Oncology, Inc.

Pharmaceutical Preparations · DE · CIK 2035832

Aktis Oncology develops targeted alpha radiopharmaceuticals for solid tumors, aiming for broad patient access

red 8-K · 90d
$1.21B
Market cap
$30.11
Last close
+2.3%
1D
+21.5%
5D
539K
Volume
Price · last 39 sessions+58.5%
May 4L $18.27 · H $31.15Jun 29
10
Total filings
May 11, 2026
Last filing
12/31
Fiscal year end

Insider Activity

◆ Cluster Buy · 6 insiders

In the 90 days to Jan 12, 2026: 6 insiders bought $114.3M.

DateInsiderActionSharesPriceValue
Jan 12, 2026Nodelman OlegDirectorBuy2,077,779$18.00$37.4M
Jan 12, 2026Mpm Oncology Innovations Fund LpTenPercentOwnerBuy1,112,777$18.00$20.0M
Jan 12, 2026Gadicke AnsbertTenPercentOwnerBuy1,112,777$18.00$20.0M
Jan 12, 2026Vida Ventures Ii-A, LlcTenPercentOwnerBuy812,455$18.00$14.6M
Jan 12, 2026Kim Helen SusanDirector,TenPercentOwnerBuy812,455$18.00$14.6M
Jan 12, 2026Foley ToddDirector,TenPercentOwnerBuy232,870$18.00$4.2M
Jan 12, 2026Nodelman OlegDirectorBuy144,443$18.00$2.6M
Jan 12, 2026Vida Ventures Ii-A, LlcTenPercentOwnerBuy22,545$18.00$406K
Jan 12, 2026Kim Helen SusanDirector,TenPercentOwnerBuy22,545$18.00$406K

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

Similar companies

Comparable business profile · signals at a glance